Merck & Company Inc (MRK)vsSight Sciences Inc (SGHT)
MRK
Merck & Company Inc
$135.97
+0.10%
HEALTHCARE · Cap: $335.46B
SGHT
Sight Sciences Inc
$8.24
+1.23%
HEALTHCARE · Cap: $390.57M
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 83579% more annual revenue ($66.57B vs $79.55M). MRK leads profitability with a 4.8% profit margin vs -46.8%. MRK earns a higher WallStSmart Score of 34/100 (F).
MRK
Avoid34
out of 100
Grade: F
SGHT
Avoid25
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-64.9%
Fair Value
$82.46
Current Price
$135.97
$53.51 premium
Margin of Safety
+27.7%
Fair Value
$7.65
Current Price
$8.24
$0.59 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Generating 4.5B in free cash flow
No standout strengths identified
Areas to Watch
Trading at 8.0x book value
ROE of 7.6% — below average capital efficiency
4.8% margin — thin
Elevated debt levels
Trading at 8.2x book value
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -69.1% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Free Cash Flow.
Bull Case : SGHT
Revenue growth of 12.5% demonstrates continued momentum.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 108.8x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.
Bear Case : SGHT
The primary concerns for SGHT are Price/Book, EPS Growth, Market Cap.
Key Dynamics to Monitor
MRK profiles as a value stock while SGHT is a turnaround play — different risk/reward profiles.
SGHT carries more volatility with a beta of 2.42 — expect wider price swings.
SGHT is growing revenue faster at 12.5% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (34/100 vs 25/100). SGHT offers better value entry with a 27.7% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Sight Sciences Inc
HEALTHCARE · MEDICAL DEVICES · USA
Sight Sciences Inc. (SGHT) is an innovative medical technology company specializing in the advancement of treatments for ocular diseases, with a particular emphasis on glaucoma management through both surgical and non-surgical approaches. The company’s diverse product portfolio, supported by a robust intellectual property framework, positions it favorably as demand for minimally invasive ophthalmic therapies escalates. By focusing on enhancing patient outcomes and refining its distribution network, Sight Sciences is set to capture significant market share in the evolving healthcare landscape, making it a noteworthy opportunity for institutional investors seeking growth in the medical technology sector.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?